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Mesenchymal stromal fibroblasts have emerged as key mediators of the
inflammatory response and drivers of localised inflammation, in part
through their interactions with resident and circulating immune cells at
inflammatory sites. As such, they have been implicated in a number of
chronic inflammatory conditions as well as in tumour progression through
modifying the microenvironment. The connection between metabolic
changes and altered phenotype of fibroblasts in inflammatory microenvi-
ronments has clear implications for our understanding of how chronic
inflammation is regulated and for the development of new anti-inflamma-
tory therapeutics. In this review, we consider the evidence that changes to
fibroblast metabolic state underpin chronic inflammation. We examine
recent research on fibroblast metabolism in inflammatory microenviron-
ments and consider their involvement in inflammation, providing insight
into the role of fibroblasts and metabolism in mediating inflammatory dis-
ease progression namely cancer, arthritis and fibrotic disorders including
chronic kidney disease, pulmonary fibrosis, heart disease and liver disease.
Introduction
Fibroblasts are spindle-shaped mesenchymal stromal
cells that are found in a wide variety of parenchymal tis-
sues. Primarily, they are believed to contribute to the
homeostasis of the extracellular matrix (ECM), being
capable of synthesising collagen, glycosaminoglycans,
proteoglycans and other ECM proteins, thereby helping
to maintain the structural architecture of tissues [1].
However, in inflammatory microenvironments, there
is now evidence that fibroblasts undergo major
changes in cellular phenotype, switching to a more
active, invasive and inflammatory phenotype. As a
result, fibroblasts have been implicated as central
mediators of tumour progression and a number of
chronic inflammatory disorders including fibrosis and
inflammatory joint pathologies [2]. A key driver of the
phenotypic change of fibroblasts within inflammatory
environments is now believed to be changes in the
metabolic state of the cell. In normal physiological
conditions, quiescent mesenchymal stromal fibroblasts
exhibit a relatively high metabolic rate, compared to
other cell types, maintaining substrate utilisation and
ATP generation via glycolysis, pentose phosphate
pathway and the tricarboxylic acid cycle (TCA) [3].
This high metabolic activity has been attributed to the
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state of continuous degradation and synthesis of
macromolecules and membrane components through
autophagy, the detoxification of free radicals through
generation of increased NADPH for glutathione and
thioredoxin and the maintenance of ECM via biosyn-
thesis of ECM proteins [3,4]. However, in inflamma-
tory disease pathologies, there is now evidence that
fibroblasts adopt an activated, highly metabolic pheno-
type, which is associated with disease progression by
contributing to the inflammatory microenvironment
through secretion of pro-inflammatory cytokines and
structurally remodelling ECM to facilitate aberrant
cellular invasion and growth (Fig. 1). Indeed, in inflam-
matory joint conditions like rheumatoid arthritis (RA),
activated synovial joint fibroblasts are recognised as
central contributors of the invasive, degradative and
highly inflammatory pannus–cartilage junction micro-
environment. It has been proposed that this inflamma-
tory-activated fibroblast phenotype is fuelled by an
upregulation of the aerobic glycolysis pathway, provid-
ing rapid generation of both ATP and biosynthetic




There is now a large body of evidence for the role of
both the tumour microenvironment and metabolism in
supporting tumour progression and in drug resistance.
Indeed, the use of alternative carbon sources as well as
metabolic support and metabolite exchange between
stroma and tumour cells termed the ‘reverse Warburg’
effect is now being discussed as a means of energy sus-
tenance for cancer cells in the tumour environment
[5,6]. Therefore, understanding the role of metabolism
in mediating the phenotype of cancer-associated
fibroblasts (CAFs), which are amongst the most abun-
dant cell type in the tumour microenvironment, may
have important implications with regards to identifying
new therapeutic stratagems.
Derived from mesenchymal stromal cells, CAFs
adopt an activated fibroblast phenotype not dissimilar
to the phenotype of myofibroblasts present in inflam-
matory and fibrotic conditions. In this active pheno-
type, they promote tumour growth and invasion by
supporting remodelling of the ECM via the production
of ECM components such as type I and type II colla-
gen as well as fibronectin [7–10]. Importantly, CAFs
also promote angiogenesis and invasion by contribut-
ing to the tumour inflammatory microenvironment. For
example, CAFs secrete pro-inflammatory cytokines
and chemokines that recruit innate immune cells,
including macrophages [11], monocytes [12] and neu-
trophils [13], to the tumour environment. Furthermore,
CAFs also participate in antigen cross-presentation
[14], which promotes CD4+ T-cell activation and
reduction of CD8+ T cells [15,16] and can promote
invasion through activation of IL-1 signalling [17].
Importantly, there is now increasing evidence that
the activated, tumour-promoting, phenotype of CAFs
is underpinned by changes in metabolic activity.
During their differentiation, CAFs upregulate the gly-
colytic enzymes hexokinase 2 (HK2) and phospho-
fructokinase (PFKL) in order to support the shift to
glycolysis for rapid ATP generation [18]. The increase
in HK2 in turn increases p27 protein expression via
a-ketoglutarate. Since cyclin-dependent kinase 2 is
inhibited by p27, this results in activation of the
G1/S checkpoint, suggesting a link between fibroblast
metabolic status and cell cycle [18]. Furthermore, the
increased glycolytic activity of CAFs leads to greater
lactate production [19], which together with an
increase in the lactate exporting monocarboxylate
transporter 4 (MCT4) [19] provides a greater source
of lactate to cancer cells. Critically, despite being dis-
missed for many years as a waste product, lactate is
now considered to be a key energy source for tumour
cells to fuel oxidative phosphorylation [19,20]. Indeed,
blocking MCT transporters provides a possible ave-
nue for disrupting CAF cancer metabolic symbiosis
with genetic ablation of MCT4 expression overcom-
ing adaptive resistance of cancer drug therapies [21].
Another aspect of CAFs metabolic reprogramming
is the downregulation of the TCA cycle, with
decreased isocitrate dehydrogenase 3a (IDH3a)
observed in transforming growth factor beta 1 (TGF-
b1)-induced differentiation of CAFs [22]. In this study,
knockdown of IDH3a in primary fibroblasts resulted
in increased glucose uptake and lactate production
with concomitant decrease in oxygen consumption,
whereas overexpression reduced TGF-b1-induced basal
levels of glucose uptake and lactate production as well
as increasing basal oxygen consumption [22]. In addi-
tion, CAFs are also reported to exhibit increased levels
of glutamine and ketone bodies, both of which could
provide metabolites required for oxidative phos-
phorylation in cancer cells [21]. Indeed, it has been
postulated that glutamate is secreted into tumour
microenvironment by cancer cells, is internalised by
CAFs and recycled into glutamine for uptake by can-
cer cells for glutaminolysis and nucleotide production
[23]. To this end, it has been shown that glutamine
anabolic pathways are increased in CAFs from ovarian
2 The FEBS Journal (2020) ª 2020 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of
Federation of European Biochemical Societies
Fibroblast metabolism and inflammatory disease H. Farah et al.
adenocarcinoma patients, compared to normal ovarian
fibroblast [23].
It is currently unclear what the trigger is for the
metabolic reprogramming exhibited by CAFs. How-
ever, interestingly, a reduction in the mitochondrial
transcription factor A (TFAM) in stromal fibroblasts
was reported to cause mitochondrial dysfunction and
metabolic reprogramming consistent with the CAF-ac-
tivated metabolic phenotype of increased glycolysis
and overproduction of lactate [24]. Notably, these
TFAM-deficient fibroblasts promoted tumour growth
in a human breast cancer xenograft model and
increased the mitochondrial activity of adjacent epithe-
lial cancer cells [24].
Fig. 1. Dysregulated metabolic pathways of activated stromal fibroblasts. Fibroblasts in their nonactivated quiescent state maintain relatively
high levels of energy production using glycolysis. However, activation via environmental stimuli such as inflammation results in an altered
metabolic phenotype common to multiple fibroblast pathologies that increases key metabolic pathways including glycolysis, oxidative
phosphorylation, lactate production, pentose phosphate pathway and glutamine metabolism.
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Fibroblast metabolism in chronic
inflammatory disorders
Synovial fibroblasts and inflammatory joint
disease
Synovial fibroblasts are amongst the most important
and abundant stromal cells at the joint synovium and
contribute to the pathology of RA and other inflam-
matory joint diseases including osteoarthritis (OA),
juvenile idiopathic arthritis, ankylosing spondylitis and
psoriatic arthritis. Located at the synovial sublining
and the lining layer, they are responsible for establish-
ing cartilage integrity and the lubrication of the syn-
ovial joint by secreting ECM components into the
synovial fluid. However, in RA, synovial fibroblasts
adopt an inflammatory and invasive phenotype. RA
synovial fibroblasts are hyperplastic and proliferate
faster than non-RA synovial fibroblasts, resulting in
the formation of pannus-like structures as they lose
contact inhibition, become anchorage-independent
and upregulate expression of collagenases such as
matrix metalloproteases and aggrecanases including
ADAMTS4/5 that promotes cartilage degradation and
perpetuate inflammation of the joint [25]. A similar
inflammatory phenotype has recently been reported in
OA, particularly in individuals who are obese. Obese
OA synovial fibroblasts were more proliferative and
exhibited a more inflammatory transcriptomic pheno-
type, compared to either normal-weight OA patient
fibroblasts or to non-OA diseased fibroblasts [26].
Synovial fibroblasts are also innate immunity effec-
tors as they express a number of pattern recognition
receptors such as Toll-like receptors 1-7, retinoic acid-
inducible gene I and melanoma differentiation-associ-
ated protein 5 [27,28]. Exogenous peptidoglycan as
well as endogenous ligands such as RNA from necro-
tic cells, hyaluronan, heat-shock protein and fibrinogen
is present in the RA synovial joint and can potentially
activate synovial fibroblasts through TLR2 and TRL4
signalling and upregulate the expression of pro-inflam-
matory cytokines and chemokines [29]. Stimulation of
TLR3 with Poly(I:C) ligand along with tumour necro-
sis factor a (TNF-a) and IL-1b in synovial fibroblasts
resulted in a cytokine secretome similar to RA syn-
ovial fluid, suggesting that the synovial fibroblast con-
tributes considerably to the inflammatory environment
at the RA synovial joint [29]. Indeed, synovial fibrob-
lasts are major contributors to the inflammatory joint
environment in both OA and RA disease through the
release of pro-inflammatory cytokines. In OA, the
increase in synovial fluid concentrations of TNF-a, IL-
6 and IL-8 in obese patients is attributed to the
increased secretion of these cytokines from obese syn-
ovial fibroblasts [30].
As in other inflammatory microenvironments, there
is now growing evidence that synovial fibroblasts
switch to a highly metabolically active state in the
joints of patients with inflammatory disease. In Vas-
quez’ model, a key hallmark of rapidly proliferating
mammalian cells is a shift towards aerobic glycolysis
and a reduction in mitochondrial respiration when glu-
cose uptake is not the rate-limiting factor providing an
energetically favourable catabolic state that solves the
inherent physicochemical constraint of molecular
crowding [31]. This switch from a resting regulatory
state to a highly metabolically active state provides the
macromolecules such as bioactive metabolites and
nucleic acid intermediates required to promote and
sustain the hyperplastic and hyperinflammatory state
(Fig. 1). GC/TOF-mass spectrometry-based metabolo-
mic profiling of RA synovial fibroblasts has revealed
an alteration in sugar and amino acid metabolism as
well as lipolysis as related to synovial hyperplasia and
inflammation, providing further evidence of a link
between aberrant metabolism and inflammation in RA
synovial fibroblasts [32]. This change in basal glucose
metabolism has also been observed in other studies
and stimulation with pro-inflammatory cytokines has
been shown to upregulate glycolysis in RA synovial
fibroblasts, similarly to that observed in CAFs (Fig. 2)
[32,33]. Glucose starvation reduced the prolifera-
tion and migration of RA synovial fibroblasts and
decreased the levels of the pro-inflammatory cytokine
IL-6 and degradative enzyme matrixmetalloprotease
(MMP)1 and MMP3 [33]. Key glycolytic enzymes like
phosphoglycerate kinase 1 (PGK1) and phospho-
fructo-2-kinase/fructose-2,6-bisphosphatase 3 enzyme
(PFKFB) play a critical role in the RA synovial
fibroblast phenotype. High levels of glycolytic enzyme
PGK1 were observed in the blood and synovial tissue
of RA patients and silencing of PGK1 in RA synovial
fibroblasts using anti-PGK1 siRNA reduced the secre-
tion of pro-inflammatory cytokines IL-1b and IFN-c
[34]. Inhibition of fructose 2,6-bisphosphate produc-
tion resulted in reduced levels of IL-6 and the invasive
phenotype of RA synovial fibroblasts [35,36]. Inhibit-
ing PFKFB3 glycolytic enzyme in RA synovial fibrob-
lasts with 3PO (dipyridinyl-propenone), a small
molecule compound, which selectively inhibits PFK-2
activity of the PFKFB3 enzyme, reduced fructose-2,6-
bisphosphate and lactate levels as well as reducing the
secretion of pro-inflammatory cytokines [36]. Along-
side this, silencing of TNFa with RNAi treatment
decreased expression of glucose transporter glucose
transporter 1 and glyceraldehyde 3-phosphate
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dehydrogenase [36], providing further evidence of the
connection between the metabolic state of the cell and
the inflammatory microenvironment in which they
exist.
Metabolomics data of RA synovial fibroblasts have
also highlighted the upregulation of the pentose phos-
phate pathway which is involved in promoting cell
proliferation, invasiveness and inhibition of apoptosis,
thereby contributing to pannus formation (Fig. 2) [37].
Similarly to activated myofibroblasts, RA synovial
fibroblasts have also shown a dependency on glutamine
metabolism, with GC/MS metabolomics showing
increased glutamine metabolism and PCR analysis show-
ing increased expression of glutaminase-1 (GLS1) [38].
Glutamine deprivation resulted in reduced RA synovial
fibroblast proliferation and treatment with small mole-
cule inhibitor compound 968 (5-(3-bromo-4-(dimethy-
lamino)phenyl)-2,2-dimethyl-2,3,5,6-tetrahydrobenzo[a]
phenanthridin-4(1H)-one) ameliorated autoimmune
arthritis and reduced the number of synoviocytes in SKG
mice [38].
TLR2 receptors are capable of inducing mitochon-
drial mutations in RA synovial fibroblasts, inducing
ROS generation, increasing lipid peroxidation and
changing the ultrastructure of RA synovial fibroblast
mitochondria [39]. Furthermore, TLR2 activation was
capable of reducing mitochondrial respiration and
attenuating ATP synthesis [39]. However, inhibiting
the glycolytic pathway, using small molecule inhibitor
3-(3-pyridinyl)-1-(4-pyridinyl)-2-propen-1-one (3PO),
resulted in reducing TLR2-induced RA synovial fibrob-
last invasion and migration and attenuated pro-inflam-
matory cytokines IL-6, IL-8, MCP-1 and RANTES
production [39]. 3PO also reduced the intracellular con-
centration of lactate, another key metabolite which
induces IL-17 production in CD4+ T cells in RA [40,41].
Fibroblasts and fibrosis
Fibroblast-mediated ECM remodelling is essential for
normal tissue structural integrity. However, both
trauma and inflammation are known to alter ECM
homeostasis. In chronically inflamed tissues, cytokines
such as TNFa, IFNy and TGF-b regulate the expres-
sion of ECM proteins [42], which have been shown to
alter the inflammatory status of fibroblasts. For exam-
ple, Tenascin C, an ECM protein that is generated de
novo in chronic inflammatory conditions, interacts
with TLR4 receptors in macrophages and synovial
fibroblasts of RA patients [42].
Critically, a recent study by Zhao et al., [43] found
that dermal fibroblast metabolism was intricately
linked with ECM homeostasis. Genomewide transcrip-
tomic data of human skin fibrosis postradiation ther-
apy compared to age-matched healthy controls showed
a downregulation in oxidative phosphorylation, fatty
acid oxidation (FAO) and TCA cycle activity, along-
side a concomitant increase in glycolytic processes [43].
Indeed, induction of peroxisome proliferator-activated
receptor signalling using caffeic acid in dermal human
primary fibroblasts reduced production of profibrotic
proteins and blocking glycolysis using 2-deoxy-D-glu-
cose downregulated ECM protein levels [43].
Research into chronic kidney disease (CKD) has
implicated renal fibrosis as a cause of end-stage renal
failure. A key culprit of renal interstitial fibrosis is
Fig. 2. Commonality in metabolic signatures of activated stromal fibroblasts. Activation of stromal fibroblasts in multiple inflammatory
pathological conditions, including CAFs, RA synovial fibroblasts and fibrotic myofibroblasts in lung, renal and cardiopathy disorders, results in
an altered metabolic state. Changes occur in key metabolic processes including upregulation of the pentose phosphate pathway, aerobic
glycolysis, glutamine metabolism and oxidative phosphorylation in CAFs and synovial fibroblasts. + symbols represent the strength of
evidence and degree of pathway activation.
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activated fibroblasts, which aggregate and produce
large amounts of ECM components that contribute to
progression of CKD [44,45].
Notably, in vitro studies have shown that activated
renal interstitial fibroblast stimulated with TGF-b
exhibits decreased mitochondrial respiration and
increased expression of glycolytic enzymes HK1,2 and
PKM2 as well as increased aerobic glycolysis similar
to that observed in dermal fibroblast at sites of skin
fibrosis [43,46]. Similar findings have been demon-
strated in vivo, using the unilateral ureteral obstruction
mouse model of renal interstitial fibrosis, where
increased expression of glycolytic enzymes hexokinase
(HK) and pyruvate kinase M2 (PKM2) was observed
in renal tissue [46,47].
Fibroblasts are also key culprits in pulmonary
fibrosis, a condition which impairs respiratory gas
exchange. Lung fibroblasts under healthy conditions
remain in a quiescent state, with little collagen pro-
duction. However, in disease conditions they undergo
a major transformation, differentiating into myofi-
broblasts that exhibit increased proliferation and
greater ECM production. Alongside this change in
fibroblast phenotype, there is a shift in metabolic sta-
tus of these activated cells towards aerobic glycolysis,
which is dependent on the increased expression of the
glycolytic enzyme PFKFB3 [48]. Indeed, it has been
shown that inhibiting glycolysis using the PFKFB3
inhibitor 3PO attenuated the differentiation of lung
fibroblasts into activated myofibroblasts and reduced
their profibrotic phenotype in patients with idiopathic
pulmonary fibrosis [48]. The excessive production of
ECM components by myofibroblasts has also been
achieved in vitro by the inhibition of glutaminolysis
using glutaminase 1 inhibitors (BPTES), which cata-
bolises the conversion of glutamine into glutamate
and then a-ketoglutarate, suggesting glutamine meta-
bolism regulates increased collagen production in
myofibroblast [49].
Excessive collagen deposition in lung fibrosis has
also been linked to altered serine and glycine synthesis.
TGF-b, which promotes excessive collagen production
in idiopathic pulmonary fibrosis, was found to induce
the expression of de novo serine synthesis enzymes
phosphoglycerate dehydrogenase (PHGDH), phospho-
serine aminotransferase 1 and phosphoserine phos-
phatase, as well as the expression of the de novo
glycine synthesis enzyme serine hydroxymethyltrans-
ferase 2 (SHMT2) in primary lung fibroblasts, which
are required for collagen synthesis [50]. Indeed, IPF
patient lung tissues were found to exhibit increased
expression of PHGDH and SHMT2 [50].
Another disease state associated with fibrosis is car-
diopathy, in which activated myofibroblasts also play
a central pathological role. The development of car-
diac fibrosis is similar to the development of fibrosis in
fibrotic tissue disorders of the lung, kidney and liver.
ECM accumulation impairs cardiac function by
increasing the stiffness of tissue and inducing patho-
logical signalling within cardiomyocytes as well as
impairing mechano-electric coupling of cardiomyocytes
[51]. Myofibroblasts, as major producers of ECM com-
ponents, are intimately involved in cardiac fibrosis.
Under hypoxic conditions, cardiac fibroblasts increase
in proliferation and upregulate alpha smooth muscle
(a-SMA) expression, indicative of a switch to an acti-
vated myofibroblast phenotype [52]. Similarly, in an
in vivo model of ischaemic injury, mice displayed
reduced caveolin-1 and PTEN expression and
increased a-SMA expression in the infarct zone, which
was accompanied by increased collagen deposition and
reduced cardiac function [52].
Notably, the miRNA, miR-21, is associated with
metabolic alterations in CAFs including increased gly-
colysis, lactic acid production and expression of LDHA
and PKM2 [53]. miR-21 has been shown to promote
cardiac fibroblast to myofibroblast transformation and
myocardial fibrosis in a rat model of myocardial infarc-
tion [53,54] and increase cardiac fibrotic remodelling
and fibroblast proliferation through the CADM1/
STAT3 pathway [55].
Finally, activated myofibroblasts also play a key role
in driving fibrosis in liver cirrhosis, a known risk fac-
tor for the development of hepatocellular carcinoma
(HCC). Accumulation of ECM components at the
liver results in fibrotic scarring of liver tissue [56].
Hepatic stellate cells (HSC) are thought to be the pri-
mary ECM-producing cells that, following continuous
damage, are transformed into activated myofibroblasts
expressing a-SMA and ultimately are the primary
source of CAFs in the development of HCC [47,57]. In
brief, the damage-induced death of hepatocytes and
cholangiocytes epithelial cells of the bile duct results in
the activation of HSCs by pro-inflammatory cytokines
released by immune cells [58], which leads to activated
myofibroblast that drives hepatic fibrogenesis [59] and
CAFs that promote the proliferation and migration of
cancer cells in HCC [58].
These hepatic myofibroblasts, like in other fibrotic
conditions, secrete large amounts of ECM components
including collagen I and III and accumulate fibronec-
tin, elastin and proteoglycans [56], and have been
found in both human HCC and murine models of
HCC [47,57]. Therefore, the aforementioned metabolic
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dysregulation associated with activated myofibroblast
in cardiac and pulmonary fibrosis likely plays an
important role in the development of liver fibrosis and
HCC.
Fibroblasts and immune cell crosstalk
One aspect that likely facilitates the ability of fibrob-
lasts to regulate inflammatory microenvironments is
their interaction with immune cells. In particular, the
role that CAFs play in tumour promotion has under-
gone a conceptual shift with recent research highlight-
ing their contribution to immune suppression and
chronic inflammation due to their ability to recruit
and interact with resident or circulating immune cells.
For example, IL-6 secretion by a subset of pancreatic
CAFs (known as pancreatic stellate cells) promotes the
differentiation of immune cells into functional mye-
loid-derived suppressor cells (MDSCs) [60]. Further-
more, the release of the chemoattractant M-CSF,
SDF-1 and MCP-1 from these pancreatic CAFs pro-
motes the accumulation of MDSCs to the tumour site
[60].
CAFs also drive the recruitment of monocytes to
the tumour site and their differentiation to the M2
macrophage phenotype which contribute to the
tumour progression through secretion of pro-inflam-
matory cytokines such as IL-6, IL-8, IL-10 and TGF-b
[61]. Similarly, FAP+ CAFs like mesenchymal stem
cells in oesophageal squamous cell carcinoma are
thought to promote the migration of macrophages via
the secretion of CCL2, IL-6 and CXCL8 [62].
CAFs have also been shown to impact and modulate
adaptive immune cell function and activation. For
example, secretion of IL-6 and TGF-b from aSMA+
CAFs attenuates dendritic cell (DC) function, matura-
tion and trafficking, thus impacting on T-cell activation
and promoting T-cell anergy [61,63]. Furthermore, it
has been shown that CAF TGF-b1 signalling results in
tolerogenic DCs that promote the differentiation of T
cells towards a regulatory phenotype thereby impairing
the antitumour immune response [64]. CAFs in HCC
have also been shown to shape the metabolism of regu-
latory DCs via the upregulation of indoleamine 2,3-
dioxygenase, resulting in reduced T-cell proliferation
and the promotion of regulatory T cells (Tregs) [65]. In
breast tumours, FAP+ PDPN+ CAFs are located in
close proximity to T cells and are reported to suppress
the proliferation of T cells via nitric oxide synthase [66].
In a prostate cancer model, lactate released from gly-
colytic CAFs was associated with increased Tregs and
promoted naive T-cell polarisation via NF-kB activa-
tion and Foxp3 expression, suggesting CAFs are also
capable of shaping the metabolic environment to pro-
mote regulatory T-cell presence at the tumour site [67].
In fibrotic environments, activated myofibroblasts
promote the migration of nonresident immune cells by
inducing inflammation and by facilitating the restruc-
turing of the ECM proteins to assist immune cell infil-
tration to these fibrotic sites. In a bleomycin-induced
mouse pulmonary fibrosis fibrotic model, M2 macro-
phages were found to promote myofibroblast differen-
tiation of lung-resident mesenchymal stem cells.
Furthermore, inhibition of pulmonary M2 macrophage
infiltration attenuated the lung fibrosis [68]. Interest-
ingly, biopsies from patients with various forms of kid-
ney disease show that macrophages themselves
undergo macrophage to myofibroblast transition in
active fibrotic lesions, thereby suggesting macrophages
themselves can transdifferentiate to active myofibrob-
last and contribute directly to renal fibrosis [69]. In
addition, T cells have been shown to promote myofi-
broblast proliferation and contribute to the chronic
inflammatory state of inflammatory bowel disease [70],
where intestinal fibrosis is in part due to excessive
myofibroblast proliferation and excess ECM deposi-
tion.
In arthritis, there is substantial evidence that the
inflammatory joint pathology is exacerbated by the
interactions between synovial fibroblasts and immune
cells. In both OA and RA, the diseased synovial joint
tissue contains both innate and adaptive immune cells.
RA synovial fibroblasts release chemokines such as
CCL2 (MCP-1) when activated with pro-inflammatory
cytokines, which in turn promotes the migration of
monocytes to the synovial joint [71,72]. Activated RA
synovial fibroblasts also express CCL5 (RANTES),
which attracts T cells and monocytes [72]. Further-
more, both CCL2 and CCL5 can induce the expression
of CXCL8 (IL-8) in RA synovial fibroblasts, thereby
promoting neutrophil chemotaxis.
Synovial fibroblasts have also been shown to pro-
mote leucocyte survival and activation. Coculture stud-
ies have shown that direct cell-to-cell interaction
impedes the programmed cell death of T and B lym-
phocytes in culture [73,74]. Indeed, RA synovial
fibroblasts express IL-15, IL-16 and IL-17, which con-
tribute to CD4+ T-cell proliferation and activation in
the synovial membrane [74]. Furthermore, the expres-
sion of B lymphocyte stimulator by RA synovial
fibroblasts modulates the differentiation and prolifera-
tion of B lymphocytes, leading to the production of
autoantibodies and rheumatoid factors [75].
In addition, resting T cells also have the capacity to
act as regulators of synovial fibroblasts. Resting T
cells, with or without T-cell mitogens, induces the
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activation of synovial fibroblasts resulting in the
upregulation of pro-inflammatory cytokines IL-6, IL-8
and the putative inflammatory pain mediator prosta-
glandin PGE2 [76]. Likewise, various subsets of T lym-
phocytes (CD4+, CD8+, CD45RO+ or CD45RA+) are
capable of activating synovial fibroblasts to varying
degrees, resulting in the increased production of
inflammatory cytokines by the fibroblasts. This inter-
cellular feedforward loop, derived from cell–cell con-
tact and paracrine signalling between synovial
fibroblasts and T lymphocytes, may result in a perpet-
ual cycle of synovial inflammation, which contributes
to the chronic inflammatory state observed in RA [77].
Fibroblasts and senescence
Senescence is a molecular program that creates a state
of irreversible growth arrest and can be induced by a
wide variety of cellular stress mechanisms. Senescent
cells accumulate in ageing tissue and in a wide variety
of disease pathologies such as RA [78], tumours [79]
and fibrosis [80], and they have been shown to be cap-
able of modulating these disease pathologies in animal
models [81]. For example, senescent fibroblasts pro-
mote cellular proliferation in the tumour microenvi-
ronment, inducing the growth of malignant mammary
epithelial cells via the secretion of CXCL1, promoting
prostate epithelial cell hyperproliferation via amphireg-
ulin secretion [82] and regulating prostate tumour pro-
gression in xenograft models via the production of
through secretion of connective tissue growth factor
[83]. In RA, senescent fibroblast has been shown to
accumulate within the synovial tissue. In vitro studies
have demonstrated that senescence of RA fibroblasts
can be induced by exposure to TNFa, which is preva-
lent within the joints of RA patients. Furthermore,
such senescent RA fibroblasts secrete high levels of
pro-inflammatory cytokines including IL-6, CCL2 and
CXCL8 as well as degradative MMPs [78].
A central feature of senescent cells is their secretory
phenotype, termed the senescence-associated secretory
phenotype (SASP). Human fibroblasts, similarly to
other cell types that undergo senescence, exhibit a pro-
inflammatory SASP, with increased secretion of pro-
inflammatory cytokines and chemokines [84], which
has been implicated in mediating the pathophysiology
of inflammaging and chronic inflammatory fibrotic dis-
orders. However, importantly, several studies have
provided evidence that this inflammatory SASP is
accompanied by an altered metabolic phenotype.
In vitro, senescence in fibroblasts can be induced via
gamma radiation, proliferative exhaustion (PE) or
induction of oncogenes or ROS production, all of
which have been shown to be accompanied by changes
in fibroblast metabolism. In James et al. (2015), senes-
cent fibroblasts induced by either PE or by gamma
radiation were found to exhibit overlapping metabolic
profiles. Extracellular secretome metabolic profiles
showed increased production of citrate, tryptophan
metabolism, phospholipid and nucleotide catabolism,
whilst intracellular metabolites revealed increased gly-
colysis, gluconeogenesis, pentose phosphate pathway
and pyruvate dehydrogenase kinase (PDK) expression
[85]. Furthermore, the change in the fibroblast metabo-
lome is reported to be a dynamic process [86].
Oncogene-induced senescence in fibroblasts has also
been shown to be accompanied by changes in cellular
metabolism. For example, Ras oncogene-induced
senescence in the lung fibroblast cell line IMR-90 was
associated with metabolic changes including reduced
lipid synthesis, increased FAO and a higher rate of
basal oxygen consumption [81], whilst the suppression
of PDK1 and increased pyruvate TCA cycle flux has
implicated pyruvate dehydrogenase has a central medi-
ator of BRAF oncogene-induced senescence in human
dermal fibroblasts [87]. Notably, pharmacological or
genetic inhibition of carnitine palmitoyltransferase 1
(the rate-limiting step in mitochondrial FAO) was
found to reverse metabolic status to presenescence and
selectively inhibit the secretory, pro-inflammatory state
associated with oncogene-induced senescence [81], sug-
gesting that therapeutics that inhibit senescent CAFs




Across different inflammatory disorders and tumours,
there is now substantial evidence for the role of fibrob-
last metabolism in underpinning the pathophysiology
of inflammatory microenvironments. Such findings
clearly have implications for our understanding of how
the inflammatory response is regulated and thus the
pathways and processes that drive tumour and chronic
inflammatory disease progression.
The switch to an activated state within fibroblasts is
accompanied by a shift in metabolic status of the cell
and is observed across multiple pathologies including
in RA synovial fibroblasts, CAFs and myofibroblasts
in fibrotic disorders, suggesting commonality in the
pathophysiology of these fibroblast-associated condi-
tions (Fig. 2). The change from a resting homeostatic
state towards the activated state likely necessitates an
increased metabolic output in order to drive the
altered phenotype of the cell, such as the increased
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ECM production exhibited in activated myofibroblasts.
This change in metabolism is commonly in the form of
increased aerobic glycolysis, with activated fibroblasts
exhibiting increased expression of glycolytic enzymes
in order to drive this increased glycolysis and activated
metabolic state, for example increased expression of
hexokinase in CAFs and increased expression of
PFKFB3 in myofibroblasts, indicative of a high gly-
colytic activity as a common metabolic signature of
activated fibroblasts. Furthermore, increased glutamine
metabolism of activated fibroblasts has been reported
to be a feature of CAFs, lung myofibroblasts and RA
synovial fibroblasts.
Recognition of fibroblasts and their metabolism as
key players in mediating inflammatory and immune
responses opens up a new therapeutic area for the
identification and validation of tractable targets for
the development of therapeutic entities. Metabolism
and the tumour microenvironment are recognised as
central hallmarks of cancer [88], and as such, cancer
drug discovery research has for some time looked to
target aspects of metabolism. For example, compounds
targeting MCT1/2 to disrupt lactate transport are cur-
rently being evaluated for antitumor efficacy [89]. Fur-
thermore, inhibition of glycolysis in fibroblasts using
the small molecule PFKBP3 inhibitor 3PO has shown
efficacy in preclinical studies. In RA synovial fibrob-
lasts, 3PO reduced the secretion of pro-inflammatory
cytokines [40], and TLR2-mediated invasion and
migration [39]. Similarly, the same inhibitor attenuated
the differentiation of lung fibroblasts into activated
myofibroblasts and reduced their profibrotic phenotype
Table 1. Dysregulated metabolic pathways in stromal fibroblasts.
Metabolic pathways
Aerobic glycolysis Oxidative phosphorylation Pentose phosphate pathway Glutamine metabolism
CAFs Upregulation of HK2 and
PFKL [18]
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in patients with idiopathic pulmonary fibrosis [48]. An
alternative approach is to inhibit glutamine metabo-
lism. Targeting stromal glutamine synthetase in
tumours has been shown to inhibit tumour growth
and metastasis [90]. Furthermore, the glutaminase 1
inhibitor (compound 968) has been shown to reduce
the proliferation of RA synovial fibroblasts and to
reduce arthritis severity in an autoimmune arthritis
murine model [38]. Furthermore, reduced ECM pro-
duction in myofibroblasts has been demonstrated using
the glutaminase 1 inhibitor BPTES [49], suggesting
that inhibition of glutamine metabolism could be a
therapeutic approach for lung fibrosis. Notably, these
studies together with the commonality seen in the dys-
regulation of several of the metabolic pathways in
fibroblasts across different inflammatory pathologies
(Fig. 2, Table 1) suggest there may also be the oppor-
tunity to repurpose any developed therapeutics.
Despite these promising studies, one of the key
challenges in the metabolism therapy area is the
identification of targets within metabolic pathways
that are both tractable and can be targeted specifi-
cally. To this end, the identification of targets that
specifically mediate fibroblast metabolism and/or
their interaction with immune cells could be a
rewarding therapeutic strategy. Such an approach
requires further investigation into the metabolic
pathways that are altered in activated diseased
fibroblasts and the key genes that mediate these
pathways. An additional challenge is the heterogene-
ity of fibroblasts, with several studies having demon-
strated that specific fibroblast subsets in RA, fibrosis
and cancer can mediate inflammation and/or cross-
talk with immune cells. However, the existence of
specific subsets also represents the opportunity to
therapeutically target specific pathotypes. For exam-
ple, single-cell sequencing recently identified anatomi-
cally discrete and transcriptomically distinct
fibroblast subsets in RA that mediated inflammation
and tissue damage [91]. Studies to determine differ-
ences in the metabolism of these different fibroblast
pathotypes could identify more specific tractable tar-
gets for the development of therapeutics.
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